PRKDC and malignant glioma: Our previous studies indicated that MYT1L was overexpressed in glioblastoma cell lines and 46.9% of malignant glioma tissue samples (n = 32) [29], functioning as an oncogene in glioblastoma cells with normal DNA-PK activity.